Our Biometrics organization starts with the end in mind, deconstructing the regulatory pathway to ensure the data are reported, displayed, and captured in the most appropriate manner to support our sponsor’s development process.
At PRA, Biometrics forms a centralized, global model that integrates Portfolio Management, Biostatistics and Programming, and Data Operations. Our team of top industry experts operates across all phases and PRA divisions, allowing us to easily customize our Biometrics model and provide cost-effective solutions for any client.
PRA’s 3 Chinese Biometrics hubs offer our clients the highest quality, flexible, scalable, and multilingual Biostatistics, Programming, and Data Operations services for local, regional, and global clinical studies“
Associate DirectorBiometrics, China
The centralization of PRA’s Biometrics model offers the following:
Global standards, processes, and integrated systems
Delivery with consistency, reliability, and high quality
Team allocation based on the relevant time zone and therapeutic expertise
Industry-leading data management and Clinical Data Interchange Standards Consortium (CDISC) data conversion technology (EXACT™)
PRA has 3 Biometrics hubs in China: Beijing, Shanghai, and Dalian. These hubs offer multilingual skill support for Japanese and Korean clients and leverage more effective project structures across Asia Pacific and the rest of the world. PRA’s investment and expansion in China is a direct response to our sponsors’ needs and builds on our mission to advance global clinical drug development.
Explore PRA in China
Our Solutions and Capabilities
Biometrics forms a centralized, global model that integrates Portfolio Management, Biostatistics and Programming, Data Operations, and Medical…
We’re committed to meaningfully integrating sustainability considerations into our business practices and culture. The work we do has a global…
Managing Trials With Multiple Partners
Clinical trials are complex undertakings and whether by necessity or strategic design, an increasing number of trials are now outsourced by pharma…
The Challenges of Patient Recruitment in Oncology Trials - Part 3
A Phase I through Phase III oncology trial costs approximately $56.3 million and lasts for eight years. In 2012, it was reported that a typical…